You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Skin cancer

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma

  • Technology appraisal guidance
  • Reference number: TA544
  • Published:  17 October 2018
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
{"Message":"No stream returned from blob store for id 81deb4d2-2e37-42c5-8277-b9d016f159c3","StatusCode":"InternalServerError"}
  • Final appraisal determination document (PDF 260 KB)

    Published:
    17 September 2018
  • Committee papers (PDF 22.05 MB)

    Published:
    17 September 2018
  • Public committee slides - clinical (PDF 565 KB)

    Published:
    17 September 2018
  • Public committee slides - cost effectiveness (PDF 648 KB)

    Published:
    17 September 2018

This page was last updated: 17 September 2018

Back to top